Simple_JJ and_CC Reliable_JJ Method_NN for_IN Detection_NP and_CC Genotyping_NP of_IN Hepatitis_NP C_NP Virus_NP RNA_NP in_IN Dried_NP Blood_NP Spots_NP Stored_NP at_IN Room_NP Temperature_NP We_PP describe_VBP a_DT simple_JJ ,_, sensitive_JJ ,_, and_CC reproducible_JJ method_NN for_IN using_VBG whole_JJ blood_NN collected_VBN onto_IN filter_NN paper_NN (_( dried_VBN blood_NN spots_NNS )_) for_IN detection_NN and_CC genotyping_NN of_IN hepatitis_NP C_NP virus_NN RNA_NP that_WDT can_MD be_VB useful_JJ in_IN large_JJ field_NN studies_NNS ,_, particularly_RB in_IN settings_NNS where_WRB collection_NN ,_, preparation_NN ,_, storage_NN ,_, and_CC shipment_NN of_IN samples_NNS at_IN controlled_JJ temperature_NN can_MD be_VB difficult_JJ ._SENT Dried_VBN blood_NN spots_NNS (_( DBS_NP )_) have_VBP been_VBN used_VBN worldwide_RB for_IN the_DT neonatal_JJ screening_NN of_IN congenital_JJ disorders_NNS ._SENT Seroepidemiological_JJ studies_NNS have_VBP been_VBN conducted_VBN on_IN DBS_NP residual_JJ to_TO neonatal_JJ screening_NN to_TO assess_VB human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) prevalence_NN among_IN childbearing_NN women_NNS ._SENT Recently_RB ,_, several_JJ studies_NNS were_VBD focused_VBN on_IN DBS_NP for_IN detecting_VBG drug_NN resistance_NN mutations_NNS and_CC for_IN tracking_VBG global_JJ spreading_VBG of_IN HIV_NP type_NN 1_CD subtypes_NNS in_IN proviral_JJ HIV_NP DNA_NP ._SENT However_RB ,_, RNA_NP is_VBZ notoriously_RB less_RBR stable_JJ ,_, and_CC standardization_NN of_IN DBS_NP for_IN viral_JJ RNA_NP detection_NN would_MD be_VB of_IN great_JJ benefit_NN for_IN application_NN to_TO large_JJ field_NN studies_NNS ,_, since_IN DBS_NP collection_NN is_VBZ easy_JJ ,_, does_VBZ not_RB require_VB skilled_JJ phlebotomists_NNS and_CC expert_NN technicians_NNS ,_, and_CC is_VBZ suitable_JJ for_IN storage_NN and_CC shipment_NN to_TO laboratory_NN in_IN settings_NNS where_WRB these_DT issues_NNS are_VBP problematic_JJ ._SENT Recently_RB ,_, dried_VBD plasma_NN spots_NNS and_CC DBS_NP have_VBP been_VBN used_VBN for_IN HIV_NP RNA_NP detection_NN and_CC quantification_NN ,_, showing_VBG good_JJ correlation_NN with_IN titers_NNS obtained_VBN with_IN conventional_JJ plasma_NN samples_NNS ._SENT However_RB ,_, these_DT observations_NNS were_VBD limited_VBN to_TO short_JJ storage_NN at_IN room_NN temperature_NN or_CC at_IN 37C_JJ ,_, and_CC a_DT loss_NN of_IN viral_JJ titers_NNS occurred_VBN during_IN storage_NN ._SENT For_IN hepatitis_NP C_NP virus_NN (_( HCV_NP )_) RNA_NP detection_NN on_IN dried_VBN spot_NN samples_NNS ,_, the_DT available_JJ data_NNS are_VBP much_RB less_RBR exhaustive_JJ ._SENT A_DT complete_JJ match_NN between_IN frozen_JJ serum_NN and_CC dried_VBD plasma_NN spots_NNS ,_, though_RB with_IN a_DT loss_NN of_IN titers_NNS after_IN room_NN temperature_NN storage_NN ,_, has_VBZ been_VBN observed_VBN ._SENT This_DT study_NN was_VBD aimed_VBN at_IN developing_VBG a_DT simple_JJ ,_, sensitive_JJ ,_, and_CC reproducible_JJ method_NN for_IN using_VBG DBS_NP in_IN HCV_NP RNA_NP detection_NN and_CC genotyping_NN ._SENT The_DT study_NN complied_VBN with_IN all_DT relevant_JJ national_JJ guidelines_NNS and_CC institutional_JJ policies_NNS ._SENT Residual_JJ laboratory_NN samples_NNS of_IN EDTA-whole_NP blood_NN of_IN 39_CD HCV_NP antibody_NN (Ab)-positive_NN and_CC 16_CD HCV_NP Ab-negative_NP patients_NNS ,_, undergoing_VBG routine_JJ hematological_JJ controls_NNS ,_, were_VBD used_VBN ._SENT HCV_NP Abs_NP were_VBD determined_VBN by_IN third-generation_NN assay_NN (_( Abbott_NP Diagnostics_NP )_) ._SENT Among_IN the_DT Ab-positive_JJ patients_NNS ,_, 34_CD had_VBD HCV_NP RNA_NP levels_NNS ranging_VBG between_IN 9,640_CD and_CC 5,100,000_CD IU/ml_NN (_( Amplicor_NP HCV_NP Monitor_NP ;_: Roche_NP Molecular_NP Systems_NPS Inc._NP )_) ,_, and_CC 5_CD were_VBD HCV_NP RNA_NP negative_NN (_( Versant_NP HCV_NP TMA_NP ;_: Bayer_NP Diagnostic_NP Inc._NP )_) ._SENT The_DT HCV_NP genotype_NN was_VBD known_VBN for_IN eight_CD patients_NNS (_( four_CD had_VBD 1b_JJ ;_: two_CD had_VBD 2a/2c_JJ ;_: one_PP had_VBD 3a_JJ ;_: and_CC one_PP had_VBD 4c/4d_JJ )_) ._SENT DBS_NP were_VBD realized_VBN within_IN 5_CD h_NN from_IN venipuncture_NN by_IN carefully_RB spotting_VBG ,_, in_IN multiple_NN replicates_VBZ for_IN each_DT patient_NN ,_, 50_CD mul_NN of_IN EDTA-whole_NP blood_NN on_IN SS_NP grade_NN 903_CD filter_NN paper_NN (_( Schleicher_NP &_CC Schuell_NP Inc._NP )_) ._SENT Two_CD DBS_NP from_IN each_DT patient_NN were_VBD pooled_VBN and_CC processed_VBN for_IN each_DT assay_NN ._SENT HCV_NP RNA_NP detection_NN was_VBD performed_VBN with_IN both_DT in-house_JJ reverse_NN transcriptase_NN PCR_NP (_( RT-PCR_NP )_) and_CC transcription-mediated_JJ amplification_NN (_( TMA_NP )_) ._SENT For_IN RT-PCR_NP ,_, RNA_NP extraction_NN was_VBD performed_VBN with_IN Boom_NP technology_NN ,_, utilizing_VBG silica-based_JJ RNA_NP isolation_NN ,_, which_WDT was_VBD purchased_VBN from_IN Organon_NP Teknika_NP ._SENT Specifically_RB ,_, DBS_NP were_VBD cut_VBN ,_, placed_VBN in_IN 9_CD ml_NN of_IN lysis_NN reagent_NN ,_, rocked_VBD 2_CD h_NN at_IN room_NN temperature_NN ,_, and_CC removed_VBD ;_: supernatants_NNS were_VBD extracted_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Ten_CD microliters_NNS out_RB of_IN the_DT 50-mul_NP RNA_NP eluate_NNS underwent_VBD the_DT subsequent_JJ steps_NNS ._SENT Reverse_JJ transcription_NN was_VBD performed_VBN with_IN 50_CD U_NN of_IN Moloney_NP murine_JJ leukemia_NN virus_NN RT_NP (_( Gibco_NP BRL_NP ,_, Life_NP Technologies_NPS )_) in_IN 20_CD mul_NN ._SENT Ten_CD microliters_NNS of_IN cDNA_NN was_VBD used_VBN in_IN the_DT nested_VBN PCR_NP ,_, according_VBG to_TO reference_NN ._SENT The_DT amplified_VBN products_NNS were_VBD analyzed_VBN by_IN agarose_JJ gel_NN electrophoresis_NN (_( amplicon_NN size_NN ,_, 197_CD bp_NN )_) ._SENT TMA_NP ,_, provided_VBN by_IN Bayer_NP S.p.A._NP Divisione_NP Diagnostici_NP Italia_NP ,_, is_VBZ a_DT recently_RB developed_VBN HCV_NP RNA_NP qualitative_JJ detection_NN method_NN ,_, based_VBN on_IN 5_CD '_POS untranslated_JJ region-targeted_JJ magnetic_JJ separation_NN ,_, followed_VBN by_IN reverse_JJ transcription_NN and_CC T7_JJ RNA_NP polymerase-driven_JJ isothermal_JJ amplification_NN ._SENT DBS_NP from_IN each_DT patient_NN were_VBD soaked_VBN in_IN 500_CD mul_NN of_IN distilled_JJ water_NN supplemented_VBN with_IN 400_CD mul_NN of_IN Target_NP Capture_NP Reagent_NP and_CC were_VBD incubated_VBN at_IN 60C_JJ for_IN 60_CD min_NN ._SENT Then_RB supernatants_NNS were_VBD decanted_VBN ;_: the_DT subsequent_JJ extraction_NN and_CC detection_NN steps_NNS followed_VBD the_DT standard_JJ TMA_NP protocol_NN ._SENT A_DT total_NN of_IN 158_CD DBS_NP pairs_NNS were_VBD tested_VBN (_( 124_CD from_IN 34_CD HCV_NP patients_NNS ;_: 24_CD from_IN 19_CD HCV-negative_JJ individuals_NNS )_) ._SENT On_IN the_DT whole_NN ,_, with_IN both_DT TMA_NP and_CC RT-PCR_NP all_RB the_DT 124_CD DBS_NP pairs_NNS from_IN positive_JJ patients_NNS tested_VBD positive_JJ ,_, and_CC all_PDT the_DT 24_CD DBS_NP pairs_NNS from_IN the_DT HCV_NP RNA-negative_NP patients_NNS tested_VBD negative_JJ (_( sensitivity_NN >_SYM 99_CD %_NN ;_: specificity_NN >_SYM 95_CD %_NN )_) ._SENT No_DT genotype_NN restriction_NN was_VBD observed_VBN ._SENT The_DT detection_NN limit_NN was_VBD established_VBN by_IN limiting_VBG dilution_NN analysis_NN ._SENT Specifically_RB ,_, blood_NN samples_NNS from_IN two_CD viremic_JJ patients_NNS (_( viral_JJ burdens_NNS ,_, 604,000_CD and_CC 807,000_CD IU/ml_NN )_) were_VBD serially_RB diluted_VBN with_IN blood_NN from_IN an_DT HCV-seronegative_JJ individual_NN ._SENT Seven_CD fivefold_JJ serial_JJ blood_NN dilutions_NNS were_VBD spotted_VBN to_TO form_VB multiple_JJ replicate_JJ DBS_NP strips_NNS ._SENT Four_CD replicate_JJ pairs_NNS of_IN each_DT dilution_NN (_( 24_CD tests_NNS per_IN run_NN )_) were_VBD tested_VBN with_IN TMA_NP (_( after_IN 1_CD and_CC 5_CD weeks_NNS )_) ,_, giving_VBG a_DT total_NN of_IN 48_CD tests_NNS performed_VBN ,_, and_CC with_IN RT-PCR_NP ._SENT The_DT results_NNS ,_, shown_VBN in_IN Table_NP ,_, indicate_VBP that_IN TMA_NP was_VBD positive_JJ in_IN 100_CD ,_, 85.7_CD ,_, and_CC 75_CD %_NN of_IN DBS_NP containing_VBG ,_, respectively_RB ,_, 1,328_CD ,_, 265_CD ,_, and_CC 53_CD IU_NP of_IN HCV_NP RNA_NP ._SENT Similar_JJ sensitivity_NN was_VBD observed_VBN with_IN RT-PCR_NP (_( not_RB shown_VBN )_) ._SENT TABLE_NN 1_CD |_SYM Establishment_NN of_IN detection_NN limit_NN of_IN HCV_NP qualitative_JJ RNA_NP assay_NN (_( TMA_NP )_) applied_VBD to_TO DBS_NP To_TO evaluate_VB the_DT cross-contamination_NN risk_NN ,_, a_DT panel_NN of_IN DBS_NP strips_NNS was_VBD prepared_VBN by_IN spotting_VBG in_IN close_JJ vicinity_NN and_CC ,_, in_IN alternate_JJ order_NN ,_, 15_CD blood_NN samples_NNS from_IN HCV_NP RNA-positive_NP patients_NNS and_CC 15_CD blood_NN samples_NNS from_IN HCV_NP Ab-negative_NP individuals_NNS ._SENT Representative_NP RT-PCR_NP results_NNS are_VBP shown_VBN in_IN Fig._NN ,_, indicating_VBG a_DT complete_JJ correspondence_NN between_IN expected_VBN and_CC observed_VBN results_NNS ._SENT Similar_JJ results_NNS were_VBD obtained_VBN with_IN TMA_NP (_( not_RB shown_VBN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Detection_NP of_IN HCV_NP RNA_NP in_IN DBS_NP from_IN HCV-positive_NP and_CC -negative_JJ individuals_NNS ._SENT Detection_NN of_IN HCV_NP RNA_NP in_IN DBS_NP from_IN HCV-positive_NP and_CC -negative_JJ individuals_NNS ._SENT To_TO control_VB the_DT risk_NN of_IN cross-contamination_NN in_IN using_VBG DBS_NP for_IN HCV_NP RNA_NP detection_NN ,_, DBS_NP strips_NNS were_VBD prepared_VBN with_IN blood_NN from_IN 30_CD different_JJ patients_NNS that_WDT was_VBD expected_VBN to_TO be_VB positive_JJ (_( uneven_JJ lines_NNS )_) or_CC negative_JJ (_( even_JJ lines_NNS )_) ._SENT The_DT strips_NNS were_VBD spotted_VBN to_TO realize_VB a_DT lattice_NN of_IN alternately_RB HCV_NP RNA-positive_NP and_CC -negative_JJ samples_NNS ._SENT DBS_NP strips_NNS were_VBD wrapped_VBN in_IN their_PP$ individual_JJ paper_NN covers_NNS and_CC stored_VBD together_RB in_IN the_DT same_JJ plastic_NN bag_NN for_IN 1_CD week_NN at_IN room_NN temperature_NN before_IN the_DT assay_NN ._SENT Representative_JJ results_NNS obtained_VBN with_IN RT-PCR_NP are_VBP shown_VBN ._SENT To_TO test_VB the_DT stability_NN of_IN HCV_NP RNA_NP in_IN DBS_NP over_IN time_NN ,_, a_DT set_NN of_IN replicate_JJ DBS_NP from_IN 16_CD HCV_NP RNA-positive_NP patients_NNS was_VBD stored_VBN at_IN room_NN temperature_NN and_CC assayed_VBN at_IN intervals_NNS of_IN 2_CD to_TO 4_CD weeks_NNS over_IN an_DT 11-month_JJ period_NN ._SENT The_DT results_NNS indicate_VBP that_IN 100_CD %_NN positivity_NN was_VBD preserved_VBN along_IN the_DT whole_JJ observation_NN period_NN ._SENT To_TO test_VB the_DT suitability_NN of_IN DBS_NP for_IN HCV_NP genotyping_NN ,_, a_DT replicate_JJ set_NN of_IN DBS_NP from_IN the_DT eight_CD patients_NNS with_IN known_VBN genotype_NN ,_, stored_VBN at_IN room_NN temperature_NN for_IN 11_CD months_NNS ,_, was_VBD extracted_VBN as_RB for_IN RT-PCR_NP and_CC genotyped_JJ by_IN using_VBG the_DT Line_NP Probe_NP assay_NN (_( Bayer_NP Diagnostic_NP Inc._NP )_) ._SENT The_DT genotype_NN ,_, determined_VBN in_IN all_DT tested_VBN DBS_NP ,_, was_VBD in_IN agreement_NN with_IN that_DT obtained_VBN on_IN frozen_JJ serum_NN samples_NNS ._SENT On_IN the_DT whole_NN ,_, our_PP$ findings_NNS show_VBP that_IN DBS_NP ,_, stored_VBN at_IN room_NN temperature_NN for_IN prolonged_JJ periods_NNS ,_, are_VBP suitable_JJ for_IN HCV_NP RNA_NP detection_NN and_CC are_VBP also_RB useful_JJ for_IN HCV_NP genotyping_NN ._SENT The_DT assessment_NN of_IN HCV_NP genotype_NN distribution_NN at_IN population_NN level_NN may_MD help_VB in_IN defining_VBG the_DT epidemiological_JJ dynamics_NNS of_IN HCV_NP infection_NN ._SENT Since_IN HCV_NP genotype_NN may_MD influence_VB the_DT response_NN to_TO antiviral_JJ treatment_NN ,_, severity_NN of_IN infection_NN ,_, and_CC performance_NN of_IN diagnostic_JJ assays_NNS ,_, these_DT aspects_NNS are_VBP particularly_RB relevant_JJ in_IN view_NN of_IN the_DT possibility_NN of_IN using_VBG the_DT method_NN described_VBD here_RB in_IN large_JJ field_NN studies_NNS and_CC for_IN application_NN in_IN settings_NNS where_WRB collection_NN ,_, centrifugation_NN ,_, storage_NN ,_, and_CC shipment_NN can_MD be_VB difficult_JJ ,_, as_RB is_VBZ often_RB the_DT case_NN in_IN developing_VBG countries_NNS ._SENT 